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The remarkable efforts that are made on molecular imaging technologies
demonstrate its potential importance and range of applications. The generation
of disease-specific animal models, and the developments of target-specific
probes and genetically encoded reporters are another important component.
Continued improvements in the instrumentation, the identification of novel
targets and genes, and the availability of improved imaging probes should be
made. Multimodal imaging probes should provide easier transitions between
laboratory studies, including small animal studies and clinical applications. Here,
we reviewed basic strategies of noninvasive in vivo imaging methods in small
animals to introducing the concept of molecular imaging.1. Introduction
Recent advances in molecular imaging allow us to
visualize both cellular and subcellular processes within
living subjects at the molecular level as well as at the
anatomic level [1]. Molecular imaging is molecular-
genetic imaging for visualizing cellular processes by
combination of molecular biology and biomedical
imaging. This marvelous technique provides researchibuted under the terms o
y-nc/3.0) which permits un
is properly cited.
ase Control and Preventionattention not only in molecular cell biology but also in
related fields. Remarkable improvement of molecular
imaging was achieved in visualization, characterization,
and quantification of biologic processes by integration
of many different fields such as genetics, pharmacology,
chemistry, physics, engineering, and medicine. In
particular, the development of controlled gene delivery
and gene expression vector systems promotes generation
of various types of reporter genes for visualization, forf the Creative Commons Attribution Non-Commercial License
restricted non-commercial use, distribution, and reproduction in
. Published by Elsevier Korea LLC. All rights reserved.
Small animal molecular imaging 49example, chloramphenicol acetyltransferase, b-galacto-
sidase, luciferases, and fluorescent proteins. Conven-
tionally, a recombinant plasmid, which contains a target
gene and a reporter gene, has been used to monitor
target gene expression by assaying reporter gene
expression. However, this method cannot be used
directly in living animals because the invariable light
intensity from reporter proteins was not enough to be
visualized in animals for non-invasive imaging.
Different strategies are required for monitoring gene
expression in vivo imaging. Accumulation of specific
imaging signal for amplifying its intensity makes it
possible to visualize localization, quantification, and
repetitive determination of gene expression in vivo
noninvasive imaging [2,3]. More effective strategies
have been tried to overcome the obstacles for moni-
toring gene expression in vivo by recruiting methods
from radio-pharmaceutics and physics. Radiolabeled
small compounds and paramagnetic probes were
developed for imaging specific proteins and magnetic
signals, accelerating non-invasive molecular imaging
technology [4,5]. In recent publications, these strategies
have been reviewed by researchers for introducing the
concept of molecular imaging [6,7].
The development of molecular imaging technologies
has been facilitated by associated development of
imaging instruments as well as imaging materials such
as enhancement agents, probes, ligands, and reporter
constructs. Small animal models have a great advantage
in disease studies that are difficult or impossible to be
performed in humans. Repetitive observation is a virtue
of noninvasive small animal imaging, which provides
information about a spatial and temporal dimension in
disease development and progression. Multiple imaging
modalities, including micro-computed tomography
(CT), micro-single photon emission computed tomog-
raphy (SPECT), micro-positron emission tomography
(PET), micro-magnetic resonance imaging (MRI),
micro-ultrasonography (US), and various optical tech-
niques using fluorescence and bioluminescence, are
available for small animal imaging (Figure 1). Recently,
the resolution of some imaging modality is approaching
cellular level [8], and the advances in imaging tech-
nology have resulted in developing combined imaging
modalities, such as PET/CT, SPECT/CT, and PET/MRI
[9,10]. Using the newly developed instrumental merging
techniques, more precise localization information of
both anatomic and molecular activity can be acquired in
a single imaging session [11]. Advantages of multi-
modal approaches to molecular imaging provide better
images for visualizing cellular, functional, and
morphologic changes. Molecular and genetic changes
usually precede biochemical, physiologic, and anatomic
changes. Anatomic morphology changes can be visual-
ized by conventional imaging modalities such as CT,
MRI, US, and radiography. Biochemical and physio-
logic changes can be monitored through the use of PET,SPECT, and MRI efforts. Molecular genetic imaging
offers several different options in visualizing molecular
genetic changes, which is occurring at the beginning of
most diseases (Figure 2). The strategies for monitoring
gene expression in small animal molecular imaging are
broadly defined as direct and indirect imaging (Table 1).
Direct imaging strategies usually consist of a specific
target and a target-specific probe, and the interaction
between a target and a probe is directly related with the
intensity of imaging signal. Synthetic radiolabeled
antisense oligonucleotide can be used as a probe for
direct imaging to visualize endogenous gene expression
at the transcription level. For indirect imaging, reporter-
geneebased techniques, which have been identified and
widely used to study cell biology, are most frequently
performed for monitoring gene expression in vivo.
Reporter genes are genetic markers that easily encode
detectable proteins or involve in metabolism of labeled
probe. These markers are great tools to determine
activities of specific promoters and the factors when
they are located at the downstream of a specific
promoter/enhancer sequence. Many genes contain more
than one promoter, and promoter activities may be
specific for a disease process. By placing an imaging
reporter gene under the control of such promoter,
promoter activity can be dynamically visualized and
gene expression can be monitored. The reporter proteins
are accumulated in the cells with a promoter-reporter
construct, and the measurements of specific imaging
signals from accumulated reporter proteins provide
indirect information that reflects the level of reporter
gene expression. A variety of molecular imaging tech-
niques, including optical, nuclear, magnetic resonance
modalities, can be used for reporter imaging. Since
reporter-based imaging system represents a part of
molecular signature in cellular process, it may be useful
in gene therapy as well as an imaging tool.2. Direct Imaging for Small Animal
Molecular Imaging
The strategies of direct imaging for small animal
molecular imaging have been established using nuclear
medicine, optical, and MRI modalities with a specific
target and a target-specific probe for gene expression.
The localization and the concentration of a probe are
directly related to its interaction with a target. In
biomarker imaging, the metabolic trapping of specific
probe molecule reflects the molecular events of
a disease. Specific ligands for receptors, antibodies, or
antibody fragments (e.g., minibody, affibody) for
a specific antigen and synthetic small molecular tracers
are other examples of direct imaging probes. Recently,
synthetic small molecular tracers, such as antisense
oligonucleotide or aptamer probes for targeting specific
Figure 1. Multimodal imaging modalities for small animal imaging.
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gene expression (Figure 3).
2.1. Biomarker imaging
For visualizing downstream effects of changes in
specific molecular events, biomarker imaging can be
useful. One good example of biomarker imaging is
based on the fact that malignant tumors frequently show
elevated level of glucose utilization and glycolysis [12].Figure 2. Multimodal imaging modalitieThis imaging strategy utilizes a radiolabeled glucose
analogue [2’-fluoro-2’-deoxyglucose-(F-18) FDG] and
PET, which reflects increased glucose transport and
hexokinase activity. [F-18] FDG PET has been widely
used in clinic to access tumor diagnosis and monitor
therapeutic effect. However, biomarker imaging may
reflect more than a single protein or signaling pathway.
For [F-18] FDG PET, glucose metabolism is regulated
by many different kinds of extracellular signals such ass for preclinical and clinical research.
Table 1. Applicable molecular imaging methods for visualizing gene expression in small animals
Direct imaging
Target Probes Imaging modality
Biomarker
Glucose transporter [F-18] FDG Nuclear
Receptor Antibody Nuclear, MR
Minibody, affibody Nuclear
Peptide ligand Nuclear, MR, optical
mRNA, protein Synthetic small molecular tracer
Antisense oligonucleotide Nuclear
Aptamer Nuclear, optical
Receptor, transporter, biomarker Paramagnetic iron oxide
SPIO, MION MR
Indirect imaging (reporter gene imaging)
Reporter Probes/contrasting agents Imaging modality
Fluorescent protein GFPs, RFPs Optical
Luciferase Optical
Enzyme type reporter
HSV1-TK, [F-18] FEAU, FHBG, [I-124] FIAU, FMAU, etc Nuclear
Tyrosinase Paramagnetic iron oxide MR
Receptor type
D2R [F-18] FESP Nuclear
SSTr [I-123,124,131,Tc-99 m] octreotide Nuclear
hNET [I-123, 124,131] MIBG, Nuclear
Estrogen [C-11]ephedrine Nuclear
Transferrin [F-18] FES MR
Ferritin Paramagnetic iron oxide MR
LRP Paramagnetic iron oxide MR
Hþ
Transporter type
NIS [I-123,124,131], [Tc-99 m]O4 Nuclear
D2R Z dopamine 2 receptor; FDGZ fluoro deoxy glucose; FEAUZ 2’-fluoro-2’-deoxy-5-ethyl-1-b-D-arabino furanosyl uracil; FESZ F-18 labeled
estradiol; FESP Z fluoro ethyl spiperone; FHBG Z 9-(4-fluoro-3-hydroxymethylbutyl)-guanine; FIAU Z fluoro-2’-deoxy-1-b-D-arabinofuranosyl-5-
iodouracil; FMAU Z 2’-fluoro-2’-deoxy-5-methyl-1-b-D-arabinofuranosyl-uracil; hNET Z human norepinephrine transporter; HSV1-TK Z herpes
simplex virus-1 thymidine kinase; LRPZ lysine rich protein; MIBGZ metaiodobenzylguanidine; MIONZ micrometer sized particles harboring iron
oxide; MR Z magnetic resonance; NIS Z sodium/iodide symporter; SPIO Z superparamagnetic ion oxide; SSTr Z soma statin receptor.
Small animal molecular imaging 51the PI3 kinase/Akt pathway, mammalian Target of
Rapamycin (mTOR), c-kit, and Hif-1a activation [6].
Nonetheless, [F-18] FDG PET whole body imaging is
most widely used in clinic for tumor diagnosis and
monitoring the efficacy of anticancer therapy that take
advantages of the predeveloped radiolabeled probe. In
particular, the application of biomarker imaging for
monitoring the response of treatment is commonly used
for evaluating the efficacy of newly developed drugs.
2.2. Receptor imaging
Since the enhanced intensity of probe signal is
directly related to its interaction with a specific target,
imaging specific receptors has been evolved to improve
probe sensitivity and specificity. For this reason, radio-
labeled antibodies for a specific receptor have been used
over for the plast 20 years to visualize the localization
of the receptor. However, the use of conventional radi-
olabeled antibody has a major problem of higher back-
ground signal from non-specific binding, slowpenetration, and prolonged clearance by a larger size.
More recently, genetically engineered small fragments
of antibody, such as minibodies or affibodies, have been
introduced as imaging probes for reducing size distur-
bance and increasing affinity [13]. In addition, small
small-sized radiolabeled peptide ligands have been also
used for specific receptor imaging. Moreover, recent
advances have increased the detection sensitivity, which
provides more options for selecting probes including
fluorescent or paramagnetic nanoparticle based probes.
Tyrosine kinase HER2 is overexpressed in most
breast cancers, and a radiolabeled monoclonal HER2
antibody for targeting HER2 is a good example of
target-specific receptor imaging. A gadolinium-chelated
HER2 specific antibody was also successfully used for
magnetic-resonanceebased molecular imaging of the
HER2 receptor. A series of small fragmented antibodies
was derived from a parental HER2 monoclonal anti-
body. A variant of anti-p185 HER2 minibodies showed
high affinity to p185 HER2 as well as rapid clearance.
Figure 3. Schematic illustration of direct imaging with a target-specific probe. Stars are radioisotope labeled, fluorescent, or
magnetic probes.
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targeting properties in vivo mouse studies were less
effective than in vitro [14]. Instead of antibody libraries,
affibody molecules are selected from phage display. A
new type of molecule named (ZHER2:4)2 showed high
affinity to HER2 and the tumor was easily visualized
with a gamma camera in a xenografted mouse [15].
Radiolabeled glycosylated Arg-Gly-Asp (RGD)
peptides are also developed for targeting alpha(v) beta3
integrin, which is highly expressed on tumor vascula-
ture and plays an important role in tumor metastasis and
angiogenesis. Recent researches focus on the wider use
of a different imaging modality or multimodality using
RGD. Kiessling and colleagues [16] reported that the
RGD-labeled ultra-small super paramagnetic iron oxide
for MRI successfully accumulated in the tumor vascu-
lature of xenograft mouse model. Multimodal imaging
approach using RGD peptide was also tried, and tumor
selective localization was observed by biolumines-
cence, fluorescence, gamma scintigraphy, and SPECT
imaging [17].
2.3. Synthetic small molecular tracer imaging
The development of synthetic small molecular tracer
that specifically hybridizes to target mRNAs or proteins
provided another strategy for direct imaging, including
radiolabeled antisense (or aptamer) oligonucleotide
probes (RASONs). Efficacy of RASONs was demon-
strated for endogenous gene expression using a gamma
camera and PET imaging [18]. A newly developed
oligonucleotide-based molecule called aptamer, which
can bind to almost any targets including proteins,
peptides, antibodies, and small molecules such as DNAsand RNAs, provides a wide range of possible probes for
specific targeting. An efficient targeting example using
a MUC-1 specific aptamer has been demonstrated in
most tumors [19,20]. However, RASON imaging still
has several serious limitations, such as high background
activity, limited tracer delivery, and poor stability.
A further development of direct radiotracer imaging
strategies is required for a specific probe for each
molecular target. In recent studies, the application of
cell penetrating peptide with oligonucleotide probe is
suggested to improve the delivery efficiency of tracing
probe across the cell membrane, and the use of modified
oligonucleotide is also recommended for longer stability
of the tracing probe. Positively charged cell-penetrating
peptides, such as transactivator of transcription protein
transduction domain and arginine/lysineerich peptide
domain, have been used as conjugating peptides for
intracellular delivery of a variety of small molecules,
including oligonucleotides [21,22]. Many types of
oligonucleotide analogues, including locked nucleic
acid or peptide nucleic acid, have been reported [23],
and the structural modification prevents enzymatic
degradation of oligonucleotides from nucleases.
2.4. Paramagnetic iron-oxideebased MRI
Recently, the application of super paramagnetic
nanoparticle based probe has increase for high resolution
of in vivo MRI. This strategy uses MRI based on a T2
effect by superparamagnetic ion oxide (SPIO) nano-
particle for visualization [24]. The clinically approved
SPIO containing Fe2þ and Fe3þ ion-oxide core is coated
with carboxy dextran. A larger amount of ion oxide can
be loaded into the nanoparticle, and micrometer-sized
Small animal molecular imaging 53particles harboring iron oxides are available for this
purpose [25]. In particular, paramagnetic iron oxide has
been successfully used with a better spatial resolution in
monocyte-macrophage based liver imaging and stem cell
trafficking [26]. For imaging the gene expression, the
conjugation with a targeting peptide or oligonucleotide
with paramagnetic ion oxide has been widely used.
Although the possible toxicity of iron oxide nanoparticle
has always been a challenge, recent findings have shown
that SPIO can be safely used in mesenchymal stem cells
trafficking without changing the viability, proliferation,
and differentiation capability [27].3. Reporter Gene Imaging for Small Animal
Molecular Imaging
Although the originally devised reporter genes have
been widely utilized to study in vitro cell biology, recent
technical developments allow direct in vivo visualization
to analyze gene expression and regulation. Reporter
genes, located at the downstream of a specific promoter,
are genetic markers that encode easily detectable
proteins, and these markers become extraordinary tools
to determine the activities of specific promoters. Imaging
reporter genes uses genetic markers that involve in
metabolism of labeled probes, which are great tools for
determining activities of specific promoters and factors
when they are located at the downstream of a specific
promoter/enhancer sequence. By placing an imaging
reporter gene under the control of such a promoter,
dynamic visualization of promoter activity can be
achieved.
3.1. Optical reporter imaging
The major advantages of optical imaging modalities,
such as fluorescence and bioluminescence imaging,
include that they are simpler, cheaper, more convenient,
and more user friendly than other imaging modalities.
Another advantage, especially for bioluminescence
imaging, is their highly sensitivity for detecting low
levels of gene expression. Various optical reporter genes
constructs, which have been already used in vitro, are
available for testing the same biologic hypotheses in
living animal models (Figure 4). Combining the fluo-
rescence and bioluminescence reporter genes into
a single gene product could provide a better resolution
for the analysis of gene expression by taking advantages
of fluorescence in vitro as well as bioluminescence
in vivo. Although one of the critical components of the
optical imaging modalities is the sensitivity of detecting
devices, recent advances have greatly increased their
sensitivity. The charged coupled device (CCD) camera
is the detection device that captures photons by photo-
cathode, converting photons to electrons for amplifica-
tion. For final detection using phosphor screen, another
conversion of the amplified electrons to photons isrequired. For reducing thermal noise, this device can be
cooled down to e120C. The sensitive range of this
system is across the entire visible and near-infrared
wavelengths. However, the blue, green, and yellow
range of the light spectrum can be easily absorbed by
mammalian tissue; the red, or longer wavelength of
light, is preferable for in vivo optical imaging.
Recently, a fluorescent protein based reporter system
has become very popular for monitoring gene expres-
sion, localization, movement, and protein-protein inter-
action in vitro [28]. Imaging fluorescent proteins is
measured by the light emission from the excitation of
external source of light. Various factors are involved in
the brightness of fluorescent proteins, including folding,
maturation, extinction coefficient, quantum yield, and
the photostability of proteins. For this reason, many
types of genetically engineered variants from natural
fluorescent proteins are also developed for better
imaging. Green fluorescent protein (GFP) has been
widely used in molecular cell biology, and most GFP
variants have come from spectral shifted variants.
Synthetic variants including an enhanced GFP (eGFP)
have been developed for improving stability and
brightness of fluorescence. A number of red fluorescent
proteins (RFP) have also been developed by genetic
modification to overcome its limitations, such as tetra-
meric toxicity and incomplete maturation. Since many
wild type fluorescent proteins have a tetrameric structure
that causes aggregation and toxicity, a variety of
genetically engineered mutant RFPs show longer emis-
sion wavelength. Bright, less toxic and more suitable
RFPs for mammalian cell studies have been generated
by Roger Tsien’s group [28]. Monomers or tandem
dimers of tetrameric fluorescent proteins with very
bright fluorescence and higher photostability have been
developed and terms such as mPlum, mCherry, and
tdTomato have been used [28]. However, fluorescent
reporter imaging for in vivo small animal imaging has
major limitations, such as the requirement of an external
light source and the exponentially decreasing intensity
of light with increasing depth of the target localization.
Moreover, the sensitivity and specificity of fluorescence
imaging are frequently disturbed by endogenous tissue
autofluorescence, which results in substantial back-
ground emissions. For this reason, the proper use of
selective filters or the application of spectral analysis is
required to reduce the interference of autofluorescence
to the acquired images.
Among the various kinds of reporter genes, luciferases
are the only ones that produce light, and they do
not require an external excitation source. Because
mammalian tissue does not emit a significant amount
of light, luciferase imaging offers lower background
signal compared with fluorescence imaging. The family
of luciferase enzymes presents in certain bacteria, marine
crustaceans, fish, and insects. The Firefly luciferase
(FLuc) and Renilla luciferase (RLuc) are most commonly
Figure 4. Strategy of the promoter-reporter gene construct for monitoring gene expression using optical imaging. P is a promoter/
enhancer sequence.
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are luciferin and coelenterazine. Native luciferase of
American firefly, Photinus pyralis, produces light with
broad emission that peaks at 560 nm and above 600 nm
fraction, making it suitable for in vivo imaging. Since the
first report of Luc gene [29], this reporter gene has been
modified for improving expression in mammalian cells
by codon optimization. The peroxisomal targeting
sequence was also deleted for higher expression in
cytosol, and some of the amino acids were substituted for
shifting emission wavelength toward the red region
above 600 nm [29]. More recently, a synthetically
derived luciferase Fluc2 has been developed with
humanized codon optimization that is designed for high
expression and reduced anomalous transcription [30].
The native substrate, D-luciferin [D-(-)-2-(6’-hydroxy-
2’-benzothiazolyl) thiazone-4-carboxylic acid], is con-
verted into oxyluciferin in an magnesium:ATP complex
(Mg-ATP) dependent process. These luciferases generate
a visible light through the oxidation of an enzyme-
specific substrate in the presence of oxygen, and ATP is
also required as an additional cofactor for luciferase
imaging. For in vivo administration, it was reported that
luciferin was found to be nontoxic and well distributed in
the whole body of mouse after exogenous application
(usually intraperitoneal injection, also can use intrave-
nous route), even crossed the blood-brain or placental
barrier. In a mouse model, luciferase reaction peaked at10e20 minutes after the injection. Another type of
commonly used luciferase from Renilla emits blue light
with a 480-nm peak, limiting its use in vivo. FLuc and
RLuc are distinguishable because they use different
substrates and emit different light spectra. For this
reason, RLuc has been used for the normalization of
firefly luciferase expression. Fast induction of lumines-
cence and the short half-life of luciferin and luciferase in
bioluminescence system provide a suitable method for
monitoring transcriptional activation using these two
luciferases [30].
In vivo bioluminescence imaging was originally
developed using a bacterial infection model [31], and
a set of genes from soil bacterium Photohabus lumi-
nescens was first introduced into Salmonella bacteria.
Bacterial luciferase Lux operon consists of five poly-
cistronic genes under the same promoter, named Lux A,
B, C, D, and E. Lux A and B encode heterodimeric
bacterial luciferase and additional genes encode
substrate synthesizing enzymes such as fatty-acid
reductase enzyme complex. The lux operon has also
been reorganized and optimized for expression. Labeled
bacteria can be detected in the mouse model and rep-
resented as the location of an infection. A reduced form
of flavin mononucleotide can be used as a substrate for
bacterial luciferase, and emission peak is 490 nm.
For whole-body imaging of small animals, biolumi-
nescence reporter genes have been more widely used
Small animal molecular imaging 55than fluorescence imaging due to the higher sensitivity
and the lower background luminescence or autolumi-
nescence. However, the basic problem of optical
imaging system is the attenuation of light photons.
About 90% of bioluminescence signal flux is lost per
centimeter of tissue; thus, photon intensities detected by
CCD cameras may not proportionately or sufficiently
reflect endogenous reporter gene expression in the inner
organs of even small animals [29].
3.2. Nuclear medicine reporter imaging
Many radionuclides emitting positrons and gamma
rays have been used for a diagnosis and therapeutic
purposes. PET scanners produce the image of positron
emitters such as F-18, C-11, and I-124. To generate
planar images and tomography of gamma ray emitters,
a conventional gamma camera and SPECT have been
routinely used. I-131, I-123, In-111 and Tc-99 m are the
source of gamma emitters in these cases. For small
animal studies, several small animal imaging instru-
ments for nuclear imaging have been developed to meet
the level of spatial resolution for the basic research
requirement. Recently commercialized micro-PET
scanners have resolution of around 2 mm3, and newly
developed micro-SPECT systems have pinhole colli-
mators for high resolution [3]. Various positron and
gamma ray emitting probes and reporter genes for
nuclear imaging have been developed (Figure 5), but
choices have to be made for particular situations and
unique advantages and disadvantages of each strategy
should be considered [6,7].
The herpes simplex virus type1 thymidine kinase
(HSV1-tk) has been most widely used as a reporter gene
for radionuclide-based molecular imaging and asFigure 5. Schematic illustration of three-type reporter gene expres
labeled substrates (enzyme) or ligands (receptor) or the radioisotopa therapeutic suicidal gene for targeted gene therapy.
The expressed viral thymidine kinase phosphorylates
thymidine to thymidine-monophosphate, which is then
di-phosphorylated and/or tri-phosphorylated by many
cellular kinases. These phosphorylated compounds can
serve as inhibitors of DNA replication, blocking
DNA polymerization, which leads to cell death. Unlike
mammalian TK, HSV1-tk can phosphorylates modified
thymidine analogues, e.g., F-18 labeled 2’-fluoro-
2’-deoxy-1-b-D-arabinofuranosyl-5-iodouracil (FIAU).
Phosphorylated FIAU cannot traverse the cellular
membrane and it is retained in the cell. PET can detect
HSV1-tk gene expression by visualizing positron emis-
sion from a reporter probedF-18 labeled phosphory-
lated FIAU in this case. The magnitude of the radioactive
reporter probe accumulation reflects HSV1-tk enzyme
activity, which represents HSV1-tk gene expression.
Two types of substrates for HSV1-tk have been reported,
which are pyrimidine nucleoside derivatives and acy-
cloguanosine derivatives. Pyrimidine nucleoside deriv-
atives are similar to natural thymidine in their structure,
and they can be more sensitive probes than acyclogua-
nosine derivatives for HSV1-tk imaging. Pyrimidine
nucleoside derivatives include FIAU, 2’-fluoro-2’-
deoxy-5-methyl-1-b-D-arabinofuranosyl-uracil (FMAU),
and 2’-fluoro-2’-deoxy-5-ethyl-1-b-D-arabino furanosyl
uracil (FEAU). A tracer dose of these drugs with
radioisotopes can be successfully utilized as a probe for
monitoring HSV1-tk expression by taking advantage of
high sensitivities of PET and SPECT. Since HSV1-tk is
less substrat-specific, it can phosphorylate acyclogua-
nosine derivatives. Acycloguanosine derivatives have
been used, and newly developed antiherpetic drugs, such
as F-18 labeled acyclovir, ganciclovir, penciclovir, andsion used in nuclear imaging modalities. Stars are radioisotope
e itself (transporter type).
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found to accumulate better than older drugs in HSV1-tk
transfected cells. Since most thymidine kinase substrates
do not cross the bloodebrain barrier very rapidly, the
development of a new kind of reporter gene/probe has
been requested. Dopamine D2 receptor (D2R) system
has been introduced for this reason, which uses D2R as
an imaging reporter gene and F-18-fluoroethyl spiperone
as a radiolabeled probe.
Since conventional PET reporter gene imaging
requires the complicated substrates and expensive PET
equipment, the development of simpler and less expen-
sive system is requested. The sodium iodide symporter
(NIS) gene system, which utilizes iodide uptake driven
by the sodium ion concentration gradient across the
membrane, has been shown to be the simplest and most
applicable reporter system. In thyroid cells, sodium ion
gradient is generated and maintained by the sodium-
potassium pump (Naþ-KþATPase). An iodide enters
with two sodiums through a specific transporter, NIS. In
addition to the iodide, several other anions are trans-
ported by NIS, i.e., ClO4
e > ReO4
- > Ie  SCNe
> ClO3
e > NO3
e, in order of transport rates. Pertech-
netate (TcO4
) and perrhenate (ReO4
) are also trans-
ported by NIS, and radioactive forms (Tc-99 m or
Re-188) of such anions are important in terms of
nuclear medicine imaging and radionuclide therapy. NIS
has many advantages as an imaging reporter gene
because various probes are available, such as radio-
iodines and Tc-99 m, and their metabolism are well
understood. Unlike the D2R or HSV1-tk system using
radiolabeled ligand, NIS has no problem with associated
labeling stability because NIS directly uses radioiodine
or Tc-99 m. In addition, NIS seems to perturb cells less
because the iodide is not metabolized in most tissues and
no adverse effects have been observed except for sodium
influx. Availability of a less immunoactive human origin
gene is another important merit of NIS. Since NIS genes
are expressed on cell surfaces, reporter probes can reach
to the cells easily. Importantly, reporter gene imaging
with NIS may be more convenient, because most nuclear
medicine departments have easily access to a gamma
camera, SPECT, radioiodines, and Tc-99 m. Neverthe-
less, NIS also has several limitations. NIS occurs natu-
rally at high concentrations in the thyroid, stomach, and
urinary tract, causing difficulties in interpreting the
image. NIS system is also hampered by the rapid efflux
of radionuclides from cells, but co-transfection with the
thyroid peroxidase gene may improve radioiodine
retention in target cells.
3.3. Magnetic resonance reporter imaging
Recently developed micro-MRI units with higher
tesla have made it possible to image small animals at
higher resolution (w50 mm) [7]. Although MRI has not
been developed for reporter imaging, many trials have
been made on the development of new MRI reporters forimaging molecular events of interaction, including the
binding of specific MRI contrasting agents with specific
surface receptors, proton exchangeemediated by enzy-
matic cleavage of functional group, and the binding of
metalloprotein or MRI contrasting agents [32,33]. The
transferrin proteins are easy to bind with iron, and the
iron-loaded transferrin proteins rapidly bind to trans-
ferrin receptors. The transferrin receptor-transferrin-Fe
complex is internalized by receptor-mediated endocy-
tosis. The iron is then released from the endosome by the
acidic environment, and the released iron decreases T2
MRI signals [34]. As a reporter gene, the transferrin gene
was cloned and transfected into the target cells, showing
an elevated level of transferring receptor gene expres-
sion. Successful MRI was demonstrated using super-
paramagnetic iron oxide for imaging the expression of
transferrin receptor. The human tyrosinase enzyme
coded gene was successfully introduced and imaged in
mouse fibroblast by iron induced T1 hyperintensities
in vitro. As seen in an iron reservoir, ferritin also has
roles in reporter MRI [35]. Nonmetallic, biodegradable
MRI reporter gene encoding lysine-rich protein (LRP) is
the prototype of a potential family of genetic engineered
reporter, expressing artificial proteins with frequency-
selective contrast [36]. The endogenous contrast is
based on the transfer from amide protons or LRP to water
protons, and this proton exchange reduces MRI signal
intensity.4. Multimodality Imaging for Small Animal
Molecular Imaging
Because each imaging technology has unique advan-
tages and disadvantages, it is useful to develop multi-
modal reporter gene system and detectors compatible
with several imaging modalities. PET/bioluminescent
imaging appears to be the most amenable technology
because PET can provide three-dimensional images and
allow quantitative analyses of reporter expression, and
optical bioluminescent imaging can easily and rapidly
produce bidimensional images with high sensitivity.
The development of instruments for combined modality,
such as microPET/microCT and microSPECT/microCT,
has been increased, and instruments that permit concur-
rent, coregistered optical imaging as well as nuclear
medicine imaging are under development. These multi-
modal instruments should provide convenient and
sensitive means of bioluminescent noninvasive reporter
gene imaging with the advantage of different modalities.
For generating multimodal reporter gene system,
several strategies are being used to link the expressions
of multiple reporter genes (Figure 6). Most genomic
DNA is involved in the regulation of gene expression,
which can be exercised at the transcriptional level or at
the post-translational level. Many genes contain more
than one promoter, and the activity of a particular
Gene1 Gene2
Cistronic approach (IRES-based)
Gene1 Gene2
Gene Fusion
Gene1 Gene2
Dual Promoter approach
Gene1 Gene2
Co-Administration
P1
P1 P2 P1 P2
P1 IRES
Gene1 Gene2
Multicistronic approach (using viral 2A sequence)
P1 T2A Gene3P2A Gene4F2A
Figure 6. Strategies of promoter-reporter gene constructs for monitoring gene expression. P1, P2 are promoter/enhancer
sequences. Gene1, Gene2, Gene3 and Gene4 can be reporter genes; internal ribosomal entry site (IRES); ribosomal skipping 2A
sequence from foot-and-mouth disease virus (F2A), porcine teschovirus-1 (P2A), and Thosea asigna virus (T2A).
Small animal molecular imaging 57promoter may be specific to a diseases process. These
types of promoter are of particular interest. First, they
are a part of the molecular signature of the pathologic
process concerned, and, second, they are potentially
useful as specific promoters for gene therapy. Dual
promoter or a coadministration approach may be used
according to the purpose of research, but the level of
expression is relatively low and uncontrollable. The
most widely used strategy is a biscistronic approach
using an internal ribosomal entry site (IRES) sequence
between the two genes. Both genes are then transcribed
into a single mRNA and later translated into two
different proteins. However, the biscistronic approach,
including IRES system, has demonstrated that a biased
expression of the two transgenes with the second gene
is underexpressed. As an alternative option for multiple
reporter gene expressions is the use of ribosomal
skipping via 2A peptides. Several viruses use 2A
peptides to mediate protein cleavage, including foot-
and-mouth disease virus (F2A), equine Rhinitis A
virus, porcine teschovirus-1 (P2A), and Thosea asigna
virus (T2A). The 2A peptide consensus motif is
extremely rare and is associated with cleavage-like
activity through a ribosomal skip mechanism; the 2A
peptide impairs normal peptide bond formation without
affecting the translation of other gene. 2A peptides
have been shown to initiate the production of up to four
proteins both in vitro and in vivo. Another strategy
involves the use of a fusion gene vector, whereby two
genes are connected, and their coding sequences are in
the same reading frame to generate a single protein.
Fusion between the two reporter genes, such as FLuc
and GFP or its color shift variants, allow a dual mode
of optical imaging. This has been conventionally used
to monitor the biologic process in vitro. Since the
fusion of engineered eGFP with other reporter gene,
such as FLuc or the NIS gene, has provided successful
employment without changing their functional prop-
erties. Chimeric fusion genes or biscistronic vectors
have been used for the noninvasive imaging of reporter
gene expression, monitored by bioluminescence and
fluorescence, microPET and fluorescence, microPETand bioluminescence, and by microPET, fluorescence,
and bioluminescence [37e39].5. Application of Small-animal Molecular
Imaging
With the advantage of noninvasive in vivo imaging,
small-animal molecular imaging can be applied to
understand biologic events in preclinical studies. Link-
ing molecular imaging to gene therapy could allow
real-time assessments of therapeutic efficacy, and link-
ing an imaging reporter gene with a therapeutic gene
could become a general approach to the monitoring
of the in vivo expression of the therapeutic gene. For
monitoring endogenous gene expression, several inves-
tigators have designed specific reporter gene constructs
named, “The Cis-Promoter/Enhancer Reporter Gene
System” under the control of upstream promoter/
enhancer elements, possessing binding sites for specific
transcription factors. Once a promoter/enhancer element
has been activated due to the expression or activation of
an endogenous gene product, imaging reporter gene
expression occurs, thus enabling visualization. Using
cis-promoter/enhancer imaging reporter genes, some
intracellular biologic events, such as the activation of
specific signal transduction pathways and nuclear
receptors, can be visualized. The expression of a nonin-
vasive reporter-imaging gene in small animals offers
excellent opportunities to understand cancer progres-
sion, metastasis, and therapy. Individual animals can be
visually monitored for tumor burden at primary sites,
and the differences in tumor progression rates can be
distinguished by reporter imaging. The possibility of
metastases can be investigated, and individual responses
to alternative therapies can be repeatedly monitored.
Moreover, therapies can be altered and the conse-
quences of these alterations observed.
Small animal molecular imaging can also be applied
to monitoring in vivo distributions of immune and stem
cells. The imaging of targeted T-cell trafficking using
optical luciferase bioluminescence imaging has been
58 H. Youn, K.-J. Hongdemonstrated in several models of autoimmunity,
including collagen-induced arthritis [40] and experi-
mental autoimmune encephalomyelitis [41]. In addition,
the transplantation of cells, such as stem cells or
progenitor cells, into damaged tissues has tremendous
potential for the treatment of a number of disorders. Once
stem cells have been administered systemically or locally,
they may be able to migrate and repopulate pathologic
sites. Three important aspects of cellular implants, i.e.,
cell tracking, cell viability, and cell numbers, can be
monitored by molecular imaging [42]. Recently, the
translation into a large animal model was successfully
performed for evaluating the possibility of clinical
application. Although in vivo imaging of transplanting
mesenchyma stem cells in a porcine heart showed signs of
inflammation [43,44], this kind of pilot study could
provide precious information toward future clinical trials.
Small animal gene expression imaging techniques
provide a new means of identifying drug targets and of
preclinical testing. The ability to noninvasively image
endogenous gene expression and various intracellular
biologic phenomena, such as signal transduction, nuclear
receptor activation, and proteineprotein interactions, has
important implications for drug discovery. Current
imaging strategies, based on a suitable reporter or an
imaging probe, can provide new information on the
level, timing, and duration of action of many biologically
active gene products. The selection of optimal probes or
promoters for reporter gene expression control should
be carefully considered when monitoring the effects of
drugs on cells. Reporter gene expression imaging has
emerged as a useful means of monitoring tumor growth
and regression in preclinical models at subcutaneous,
orthotopic, or intraperitoneal sites [45,46].
6. Conclusion
Molecular imaging embraces proteomic, metabolic,
cellular biologic processes, and genetic imaging. Several
imaging probes and reporter genes have been developed,
and successful transitions from bench to bedside have
already occurred [46,47]. Unique roles of small animal
molecular imaging allow us to increase our knowledge
on the critical biologic pathways involved in disease
progression by characterizing biologic processes or
tumor properties, and provide bridges to clinical appli-
cation, i.e., in diagnosis, staging, determination of
therapeutic targets, monitoring therapy, and in the
evaluation of prognoses.
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